Provided by Tiger Trade Technology Pte. Ltd.

Aurinia Pharmaceuticals

16.10
-0.0100-0.06%
Post-market: 16.100.00000.00%19:30 EDT
Volume:745.44K
Turnover:12.03M
Market Cap:2.14B
PE:6.99
High:16.35
Open:16.28
Low:16.06
Close:16.11
52wk High:19.25
52wk Low:10.34
Shares:133.05M
Float Shares:129.00M
Volume Ratio:1.02
T/O Rate:0.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.30
EPS(LYR):2.07
ROE:66.12%
ROA:15.49%
PB:3.48
PE(LYR):7.78

Loading ...

Aurinia issues corporate presentation outlining LUPKYNIS growth strategy, aritinercept development plan

Reuters
·
May 28

Aurinia completes tender offer for Kezar, wins 80% of shares tendered

Reuters
·
May 19

Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences

TIPRANKS
·
May 11

Aurinia Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 11

Aurinia completes Kezar acquisition at $6.96 per share plus CVR

Reuters
·
May 11

Kezar Q1 net loss narrows to $5.8 million; operating loss narrows to $7.4 million

Reuters
·
May 11

Aurinia publishes corporate presentation on LUPKYNIS growth strategy in lupus nephritis

Reuters
·
May 07

Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q1 EPS $0.25, vs. FactSet Est of $0.20

MT Newswires Live
·
May 07

Aurinia Q1 net income rises 48% to $34.4 million; revenue climbs 24% to $77.7 million

Reuters
·
May 07

BRIEF-Aurinia Pharmaceuticals Q1 Product Revenue USD 73.563 Million

Reuters
·
May 07

Aurinia Pharmaceuticals Inc: Reiterates Its Guidance for 2026 Total Revenue of $315 Mln to $325 Mln

THOMSON REUTERS
·
May 07

Aurinia Pharmaceuticals Q1 Pretax Profit USD 43.925 Million

THOMSON REUTERS
·
May 07

Aurinia Pharmaceuticals Q1 Operating Income USD 41.422 Million

THOMSON REUTERS
·
May 07

Press Release: Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

Dow Jones
·
May 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Apr 30

Aurinia Pharmaceuticals announces annual shareholder meeting

Reuters
·
Apr 22

A Look At Aurinia Pharmaceuticals (AUPH) Valuation After Its Recent Leadership Overhaul

Simply Wall St.
·
Apr 06

Aurinia Pharma to buy Kezar Life Sciences for $6.955 a share plus CVR

Reuters
·
Apr 04

Aurinia Pharmaceuticals CFO Michael Hearne files initial beneficial ownership statement

Reuters
·
Apr 03

Aurinia Pharma COO Ryan Cole files initial beneficial ownership statement

Reuters
·
Apr 03